Abstract
OBJECTIVE
Insulin resistance contributes to the pathogenesis of both polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD). The main aim of the present study was the evaluation of non-invasive indices of hepatic steatosis and fibrosis in PCOS women with or without metabolic syndrome (MetS).
DESIGN
In this cross-sectional study, three non-invasive indices for hepatic steatosis [NAFLD liver fat score, lipid accumulation product (LAP) and hepatic steatosis index (HIS)] and four for fibrosis [FIB-4, aspartate aminotransferase (AST)-to-Platelet Ratio Index (APRI), body mass index (BMI)-Age-Alanine aminotransferase (ALT)-Triglycerides (BAAT) and BMI AST/ALT Ratio Diabetes (BARD)] were calculated in 314 PCOS women (77 with, 237 without MetS) and 78 controls.
RESULTS
All steatosis indices were significantly higher in the PCOS than the control group (NAFLD liver fat score: −0.139±0.117 vs. −0.976±0.159, p<0.001; LAP: 43.3±1.9 vs. 34.7±3.1, p = 0.036; HIS: 44.6±0.5 vs. 42.1±0.8, p = 0.016). FIB-4 and BAAT [fibrosis stage (F)2-4] were higher in the PCOS group (0.480±0.020 vs. 0.400±0.013, p<0.001; and 15.6% vs. 5.1%, respectively), whereas APRI and BARD were not. All steatosis indices were significantly higher in PCOS women with than without MetS (NAFLD liver fat score: 1.874±0.258 vs. −0.793±0.099, p < 0.001; LAP: 76.8±4.9 vs. 33.4 ± 1.4, p < 0.001; and HIS: 49.8±1 vs. 43±0.5, p<0.001). Of the fibrosis indices, only BAAT (F2-4: 50.6% vs. 4.2%) was higher in PCOS women with MetS.
CONCLUSIONS
Non-invasive indices of hepatic steatosis were significantly higher in PCOS, especially in the presence of MetS, whereas indices of hepatic fibrosis yielded controversial results. Further studies are warranted to evaluate the long-term outcomes of hepatic steatosis and fibrosis indices in PCOS women.
Article PDF
Similar content being viewed by others
References
Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I, 2013 Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine 44: 583–590.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41–47.
Carmina E, 2012 PCOS: metabolic impact and long-term management. Minerva Ginecol 64: 501–505.
Sanyal AJ, 2011 NASH: A global health problem. Hepatol Res 41: 670–674.
Vernon G, Baranova A, Younossi ZM, 2011 Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274–285.
Polyzos SA, Kountouras J, Zavos C, Deretzi G, 2012 Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46: 272–284.
Panidis D, Macut D, Tziomalos K, et al, 2013 Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 78: 586–592.
Polyzos SA, Kountouras J, Zavos C, 2009 Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 9: 299–314.
Baranova A, Tran TP, Birerdinc A, Younossi ZM, 2011 Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 33: 801–814.
Chalasani N, Younossi Z, Lavine JE, et al, 2012 The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005–2023.
Machado MV, Cortez-Pinto H, 2013 Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 58: 1007–1019.
Panidis D, Tziomalos K, Misichronis G, et al, 2012 Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 27: 541–549.
Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D, 2009 Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 296: E238–243.
Kotronen A, Peltonen M, Hakkarainen A, et al, 2009 Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137: 865–872.
Bedogni G, Kahn HS, Bellentani S, Tiribelli C, 2010 A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 10: 98.
Lee JH, Kim D, Kim HJ, et al, 2010 Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42: 503–508.
McPherson S, Stewart SF, Henderson E, Burt AD, Day CP, 2010 Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59: 1265–1269.
Kruger FC, Daniels CR, Kidd M, et al, 2011 APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 101: 477–480.
Ratziu V, Giral P, Charlotte F, et al, 2000 Liver fibrosis in overweight patients. Gastroenterology 118: 1117–1123.
Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA, 2008 Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57: 1441–1447.
Musso G, Gambino R, Cassader M, Pagano G, 2011 Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43: 617–649.
Cerda C, Perez-Ayuso RM, Riquelme A, et al, 2007 Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47: 412–417.
Vassilatou E, Lafoyianni S, Vryonidou A, et al, 2010 Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25: 212–220.
Qu ZY, Shi YH, Zhao DN, Jiang JJ, Ma ZX, Chen ZJ, 2010 Effect of obesity on nonalcoholic fatty liver disease in Chinese women with polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi 90: 2036–2039.
Zueff LF, Martins WP, Vieira CS, Ferriani RA, 2012 Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 39: 341–347.
Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W, 2007 Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 5: 496–501.
Jones H, Sprung VS, Pugh CJ, et al, 2012 Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 97: 3709–3716.
Markou A, Androulakis, II, Mourmouris C, et al, 2010 Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 93: 1220–1226.
Ciotta L, Pagano I, Stracquadanio M, Formuso C, 2011 Polycystic ovarian syndrome incidence in young women with non-alcoholic fatty liver disease. Minerva Ginecol 63: 429–437.
Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ, 2006 Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 91: 1741–1747.
Baranova A, Tran TP, Afendy A, et al, 2013 Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transi Med 11: 133.
Brzozowska MM, Ostapowicz G, Weltman MD, 2009 An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 24: 243–247.
Polyzos SA, Kountouras J, Tsatsoulis A, et al, 2013 Sex steroids and sex hormone-binding globulin in postmenopausal women with non-alcoholic fatty liver disease. Hormones (Athens) 12: 405–416.
Sanyal AJ, Brunt EM, Kleiner DE, et al, 2011 Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54: 344–353.
Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F, 2009 Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51: 433–445.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Polyzos, S.A., Goulis, D.G., Kountouras, J. et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones 13, 519–531 (2014). https://doi.org/10.14310/horm.2002.1493
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1493